by The Huntington’s disease is a rare and inherited neurological disorder that negatively impacts the individual’s motor and cognitive abilities. It causes uncontrolled movements, emotional issues, and loss of intellectual abilities. The disease is caused due to expansion of CAG repeats in the Huntington’s Disease (HD) gene, leading to dysfunction and death of nerve cells in the brain. The current treatment options are aimed towards reducing symptoms and maintaining quality of life, such as antipsychotics, antidepressants, and other medications. However, there is no cure currently. Various clinical trials are taking place to evaluate potential disease-modifying drugs and new gene therapies.
The global Huntington’s Disease Treatment Market is estimated to be valued at Us$ 0.55 Mn in 2024 and is expected to exhibit a CAGR Of 4.3% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics
Growing number of clinical trials is expected to boost the Huntington’s disease treatment market growth over the forecast period. For instance, in June 2021, uniQure initiated a Phase I/II clinical trial to evaluate AMT-130 gene therapy for the treatment of Huntington’s disease. Furthermore, in March 2021, Wave Life Sciences initiated PRECISION-HD clinical trials to evaluate WVE-004 for the treatment of early manifest Huntington’s disease.
In addition, increasing research funding for developing advanced treatment solutions is also expected to fuel the market growth. For example, in January 2022, National Institutes of Health awarded $36 million to support preclinical development of gene therapies for Huntington’s disease treatment. Growing awareness regarding treatment options is further expected to propel the market growth.
Segment Analysis
The Huntington’s Disease Treatment market is dominated by symptomatic medication segment accounting for nearly 50% of the market. This is because there is no definitive treatment available for the disease and medication is mainly aimed at controlling symptoms like involuntary movements, irritability and mood changes, dementia etc. Within symptomatic medication, neuroleptics sub segment holds the major share due to wide applications.
PEST Analysis
Political: Government regulations around clinical trials and drug development process have a significant impact on this market. Faster approval pathways for orphan drugs are helping companies.
Economic: As Huntington’s is a rare disease, the patient pool and potential returns are limited which discourages large investments from big pharmaceutical players. However, increasing healthcare spending is providing funding for research.
Social: Higher awareness about rare diseases and patients support groups are driving research into better treatment options. Social stigma around inherited conditions is also gradually reducing.
Technological: Advancements in gene therapies and biomarkers for early diagnosis hold promise for future disease-modifying treatments. Use of AI and big data analytics can help clinicians track disease progression better and correlate outcomes.
Key Takeaways
The Global Huntington’s Disease Treatment Market Demand is expected to witness high growth over the forecast period driven by rising prevalence of the disease and ongoing clinical trials for potential treatments. The global Huntington’s Disease Treatment Market is estimated to be valued at US$ 0.55 Mn in 2024 and is expected to exhibit a CAGR of 4.3% over the forecast period 2024 to 2031.
North America holds the largest share currently due to enhanced healthcare infrastructure and high adoption of newer drugs. However, Asia Pacific is emerging as the fastest growing region attributed to growing patient pool, rising healthcare spending and increasing focus of global companies on this region.
Key players operating in the Huntington’s Disease Treatment market are Unilever Plc., Coty Inc., Johnson & Johnson Inc., Proctor & Gamble Co., L’Oreal S.A., Revlon Inc., Kao Corporation, Avon Products Inc., Beiersdorf AG., Colgate Palmolive Company, Natura & co., and Estee Lauder Inc. Companies are investing in gene therapies and diagnostics to develop curative options.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
